Franklin Genomic Advancements ETF (HELX)

Assets	$30.79M
Expense Ratio	0.50%
PE Ratio	33.05
Shares Out	750,000
Dividend (ttm)	$0.14
Dividend Yield	0.35%
Ex-Dividend Date	Dec 30, 2025
Payout Frequency	n/a
Payout Ratio	11.55%

Volume	368
Open	41.11
Previous Close	41.03
Day's Range	40.99 - 41.11
52-Week Low	29.80
52-Week High	43.51
Beta	0.98
Holdings	71
Inception Date	Feb 25, 2020

About HELX

Fund Home Page

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is issued by Franklin Templeton.

• Asset Class: Equity
• Category: Health
• Region: Global
• Stock Exchange: BATS
• Ticker Symbol: HELX
• ETF Provider: Franklin Templeton

Top 10 Holdings

48.13% of assets

Name	Symbol	Weight
Guardant Health, Inc.	GH	9.20%
Natera, Inc.	NTRA	8.49%
Krystal Biotech, Inc.	KRYS	5.96%
Ligand Pharmaceuticals Incorporated	LGND	4.35%
Adaptive Biotechnologies Corporation	ADPT	4.31%
Twist Bioscience Corporation	TWST	3.68%
BridgeBio Pharma, Inc.	BBIO	3.34%
Travere Therapeutics, Inc.	TVTX	3.17%
Vertex Pharmaceuticals Incorporated	VRTX	2.91%
Corteva, Inc.	CTVA	2.73%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 30, 2025	$0.14334	Jan 8, 2026
Dec 30, 2021	$0.00394	Jan 7, 2022
Dec 13, 2021	$0.11415	Dec 21, 2021
Dec 14, 2020	$0.05178	Dec 23, 2020

Performance

HELX had a total return of 36.66% in the past year, including dividends. Since the fund's inception, the average annual return has been 8.59%.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP. Several fund data points are also provided by Finnhub.

Last checked:

Sep 14, 2026

Data Sources Report a data error